NO982874L - Pharmaceutical preparations with vitamin D analogues - Google Patents

Pharmaceutical preparations with vitamin D analogues

Info

Publication number
NO982874L
NO982874L NO982874A NO982874A NO982874L NO 982874 L NO982874 L NO 982874L NO 982874 A NO982874 A NO 982874A NO 982874 A NO982874 A NO 982874A NO 982874 L NO982874 L NO 982874L
Authority
NO
Norway
Prior art keywords
analogues
vitamin
pharmaceutical preparations
cyclodextrins
psoriasis
Prior art date
Application number
NO982874A
Other languages
Norwegian (no)
Other versions
NO982874D0 (en
Inventor
Karin Hoffmann
Jutta Riedl
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO982874D0 publication Critical patent/NO982874D0/en
Publication of NO982874L publication Critical patent/NO982874L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Farmasøytiske preparater, fortrinnsvis til topisk applisering, som kjennetegnes ved at det inneholder clathrater av syklodekstriner og vitamin D-analoger. Det egner seg til behandling av psoriasis.Pharmaceutical preparations, preferably for topical application, which are characterized by containing clathrates of cyclodextrins and vitamin D analogues. It is suitable for the treatment of psoriasis.

NO982874A 1995-12-21 1998-06-19 Pharmaceutical preparations with vitamin D analogues NO982874L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19549243A DE19549243A1 (en) 1995-12-21 1995-12-21 Pharmaceutical preparations containing clathrates of cyclodextrins and unnatural vitamin D analogues
PCT/EP1996/005856 WO1997023242A1 (en) 1995-12-21 1996-12-20 Pharmaceutical compositions with vitamin d analogues

Publications (2)

Publication Number Publication Date
NO982874D0 NO982874D0 (en) 1998-06-19
NO982874L true NO982874L (en) 1998-08-20

Family

ID=7781710

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982874A NO982874L (en) 1995-12-21 1998-06-19 Pharmaceutical preparations with vitamin D analogues

Country Status (12)

Country Link
EP (1) EP0869819A1 (en)
JP (1) JP2000502733A (en)
KR (1) KR19990076637A (en)
CN (1) CN1207687A (en)
AU (1) AU1306997A (en)
CA (1) CA2241205A1 (en)
DE (1) DE19549243A1 (en)
HU (1) HUP9903935A3 (en)
IL (1) IL125020A0 (en)
IS (1) IS4774A (en)
NO (1) NO982874L (en)
WO (1) WO1997023242A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538037B2 (en) 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US6566353B2 (en) 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
DE102005017775A1 (en) * 2005-04-13 2006-10-19 Schering Ag New complex of vitamin-D-compounds with 5Z,7E,10(19)-triene system and methylene derivatives of beta-cyclodextrin, useful for the preparation of medicament and to treat psoriasis
EP1993559B1 (en) 2006-02-03 2016-06-22 OPKO Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
PT3357496T (en) 2006-06-21 2020-05-12 Opko Ireland Global Holdings Ltd Therapy using vitamin d repletion agent and vitamin d hormone replacement agent
KR100822133B1 (en) * 2006-11-06 2008-04-15 한미약품 주식회사 Complex formulation for preventing or treating osteoporosis which comprises solid dispersion of vitamin d or its derivative and bisphosphonate
DK2148684T3 (en) 2007-04-25 2013-04-22 Cytochroma Inc Method of treating vitamin D insufficiency and deficiency
EP2148683A4 (en) 2007-04-25 2012-09-12 Proventiv Therapeutics Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
WO2008134518A2 (en) 2007-04-25 2008-11-06 Cytochroma Inc. Methods and compounds for vitamin d therapy
WO2008134512A1 (en) 2007-04-25 2008-11-06 Cytochroma Inc. Oral controlled release compositions comprising vitamin d compound and waxy carrier
CN106853250A (en) 2008-04-02 2017-06-16 赛特克罗公司 Method, composition, purposes and kit for vitamin D deficiency and associated disorders
EP2552484B1 (en) 2010-03-29 2020-01-08 Opko Ireland Global Holdings, Ltd. Methods and compositions for reducing parathyroid levels
KR101847947B1 (en) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 Stabilized modified release vitamin d formulation
WO2016020508A2 (en) 2014-08-07 2016-02-11 Opko Ireland Global Holdings Ltd. Adjunctive therapy with 25-hydroxyvitamin d
US11173168B2 (en) 2016-03-28 2021-11-16 Eirgen Pharma Ltd. Methods of treating vitamin D insufficiency in chronic kidney disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177586B (en) * 1978-12-19 1981-11-28 Chinoin Gyogyszer Es Vegyeszet New process for preparing stable inclusion complexes of vitamine d with cyclodextrin
JPS5910562A (en) * 1982-07-07 1984-01-20 Teijin Ltd Preparation of pre-1alpha-hydroxycholecalciferol compound
JPS5936656A (en) * 1982-08-23 1984-02-28 Teijin Ltd Novel clathrate compound and drug containing said compound as active component
JPS60120812A (en) * 1983-12-02 1985-06-28 Teijin Ltd Remedy for diabetic osteopenia
EP0437225B1 (en) * 1990-01-10 1994-04-20 F. Hoffmann-La Roche Ag Topical preparations
IL107185A (en) * 1992-10-06 1998-02-22 Schering Ag Vitamin d, 25-carboxylic acid derivatives and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
DE19549243A1 (en) 1997-06-26
AU1306997A (en) 1997-07-17
KR19990076637A (en) 1999-10-15
CN1207687A (en) 1999-02-10
CA2241205A1 (en) 1997-07-03
HUP9903935A3 (en) 2000-05-29
IL125020A0 (en) 1999-01-26
NO982874D0 (en) 1998-06-19
IS4774A (en) 1998-06-15
WO1997023242A1 (en) 1997-07-03
HUP9903935A2 (en) 2000-03-28
EP0869819A1 (en) 1998-10-14
JP2000502733A (en) 2000-03-07

Similar Documents

Publication Publication Date Title
NO982874L (en) Pharmaceutical preparations with vitamin D analogues
DK0677039T3 (en) Cyclobutane derivatives such as squalene synthetase and protein farnesyl transferase inhibitors
DK0650483T3 (en) (3R, 4R) -Delta6-tetrahydrocannabinol-7-acids
NO963860L (en) Isoprenyl transferase inhibitors
NO20030374L (en) Cyclopentanoindoles, preparations containing such compounds and treatment methods
NO954342L (en) Erythropoietin analog mixtures, as well as processes for their preparation
NO981628L (en) (Methylsulfonyl) phenyl-2- (5H) -furanones as cox-2 inhibitors
NO974572L (en) Cyclodextrin Compounds, Methods of Preparation and Use
TR199700726T1 (en) Farnezil transferase inhibitors and their preparations.
DK0915898T3 (en) Crystal form I of clarithromycin
TR200100922T2 (en) Application of active substances through the lungs.
NO980317L (en) Use of Calendula glycosides for the treatment of psoriasis
NO944430D0 (en) 4-mercaptoacetylamino [2-benzazepinone (3) derivatives and use as enkephalinase inhibitors
IS4404A (en) Sterol derivatives to control rheumatoid arthritis
NO954878L (en) pyrrole
NO934706L (en) Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridines
NO983530L (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
ES2187648T3 (en) METHOD FOR THE ADMINISTRATION OF PHARMACOS FOR GENE THERAPY.
MX9101958A (en) AMINOSULFONYL UREA ACAT INHIBITORS
AU5805096A (en) Transdermal therapeutic system (TTS) for the administration of testosterone
NO982229D0 (en) Sulfur-containing di-tert-butylphenol compounds useful as anti-inflammatory agents
ES2120667T3 (en) L-CARNITINE SALT AND THE COSMETIC AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT FOR THE TREATMENT OF DERMATOSIS.
AU1469097A (en) Pharmaceutical compounds
AU1153400A (en) New transcription factor of mhc class ii genes, substances capable of inhibitingthis new transcription factor and medical uses of these substances
NO975682L (en) Pyridiniminyl-1,2-benzisoxazoles and benzisothiazoles as anti-psychotic agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application